We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Siemens Healthineers - Laboratory Diagnostics

Download Mobile App

Noninvasive Biomarker Tests Could Eliminate Painful Liver Biopsies

By LabMedica International staff writers
Posted on 08 Sep 2023
Print article
Image: Noninvasive biomarker tests could be alternatives to painful liver biopsies (Photo courtesy of 123RF)
Image: Noninvasive biomarker tests could be alternatives to painful liver biopsies (Photo courtesy of 123RF)

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as NASH, is a severe illness. Once the liver begins to scar, the risk of cirrhosis, liver cancer, and death significantly increases. Unfortunately, symptoms of MASH often do not appear until the disease reaches its advanced stages, typically when cirrhosis has developed. Currently, the sole method to diagnose MASH in patients is through liver biopsies. However, this approach offers insights from only a small portion of the liver and fails to provide an accurate overall assessment of the patient's condition. Liver biopsies are also painful, invasive, and expensive for patients. Despite some companies developing blood and imaging biomarker tests, none have met the stringent requirements for FDA regulatory approval. Now, a consortium dedicated to investigating noninvasive tests for liver disease has achieved a significant milestone by demonstrating the effectiveness of five such tests, moving closer to regulatory approval.

The research to evaluate blood and imaging biomarker tests for liver disease is part of NIMBLE – the Noninvasive Biomarkers of Metabolic Liver Disease project – was led by the Virginia Commonwealth University (VCU, Richmond, VA, USA). The NIMBLE biomarker tests were rigorously compared to established measures, including the FIB-4 index used to assess liver health. Any biomarker test that matched or exceeded the performance of existing lab tests was assessed for its potential use in diagnosing MASH and related conditions. Over 1,000 patients participated in this research. These five biomarker tests hold promise for diagnosing MASH and related conditions, providing a noninvasive alternative to liver biopsies. This development is expected to encourage patient participation in future clinical trials, which would otherwise necessitate invasive liver biopsies. Additionally, the use of noninvasive blood tests could significantly reduce the cost of conducting such studies, thus fostering greater interest in drug development. Equally important, these tests could be easily administered in a doctor's office.

“This brings us a step closer to having simple blood-based tests that can be ordered virtually in any clinical setting and will provide access to care to patients,” said Arun Sanyal, M.D., a professor at the VCU School of Medicine. “Such a step will facilitate our ability to identify those most at risk of outcomes and target them for therapy. It will also serve as a foundation for prognostic, disease monitoring and treatment-response biomarker development.”

Related Links:

Platinum Supplier
Xylazine Immunoassay Test
Xylazine ELISA
Gold Supplier
Digital Pathology Solution
Blood Mixer Roller
CAPPRondo Blood Mixer Roller
Enterovirus 71/Coxsackievirus A16/Enterovirus RNA Test
Detection Kit for Enterovirus 71/Coxsackievirus A16/Enterovirus RNA

Print article


Clinical Chemistry

view channel
Image: The new assays are designed to run on the B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyzer (Photo courtesy of Thermo Fisher)

Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia

Preeclampsia is a life-threatening blood pressure condition that can arise during pregnancy and the postpartum phase. This severe pregnancy complication is a primary cause of maternal and fetal mortality... Read more


view channel
Image: The US FDA has cleared HemoScreen point of care CBC for direct capillary sampling (Photo courtesy of PixCell Medical)

Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput

The world’s only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked, and TGA-approved for point-of-care use has now been granted FDA 510(k) clearance for direct capillary... Read more


view channel
Image: Immune cells present long before infection predict flu symptoms (Photo courtesy of Shutterstock.com)

Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms

For decades, if not centuries, scientists have struggled to solve the mystery of why certain individuals fall ill to infections while others remain unaffected. In an impressive development, researchers... Read more


view channel
Image: The rapid diagnostic test could pinpoint the correct antibiotic for infection treatment in under an hour (Photo courtesy of Microplate Dx)

Point-of-Care Device to Reduce Antibiotic Susceptibility Testing Time from Days to Minutes

Antimicrobial resistance (AMR) is a significant global health issue, currently leading to over 1.27 million deaths worldwide each year. By 2050, AMR could be causing up to 10 million deaths annually, surpassing... Read more


view channel
Image: The Tasso+ device has received CE Mark certification (Photo courtesy of Tasso)

Groundbreaking Blood Lancing Device Obtains Microliter Capillary Whole Blood Samples Painlessly

A convenient, virtually pain-free blood lancet that collects whole liquid blood samples has received CE Mark designation, making the patient-centric, high-volume blood collection solution available in... Read more


view channel
Image: A new electrochemical device can quickly and inexpensively identify people at greatest risk for osteoporosis (Photo courtesy of ACS Central Science, 2023)

Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop

With the global increase in life expectancy, the incidence of age-related conditions like osteoporosis is increasing. Osteoporosis, affecting around 200 million individuals worldwide, has a higher incidence... Read more


view channel
Image: The global fully automatic electrolyte analyzers market is projected to reach close to USD 0.77 billion by 2032 (Photo courtesy of 123RF)

Global Fully Automatic Electrolyte Analyzers Market Driven by Surge in Demand for Point-of-Care Testing

Fully automatic electrolyte analyzers can measure the levels of electrolytes in various bodily fluids like blood and plasma. Electrolytes are ions that have an electrical charge and are essential for multiple... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.